The Top 5 Biosimilar Articles for the Week of February 1

Here are the top 5 biosimilar articles for the week of February 1, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 1, 2021.

Number 5: In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.

Number 4: Using a combination of step therapy and parity reimbursement, pharmacy benefit manager (PBM) Magellan Rx Management has achieved a 90% success rate in biosimilar authorizations for the period from July 2019 to May 2020.

Number 3: Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.

Number 2: Pfizer's investment in biosimilars is starting to pay off, as it now ranks these agents among its top revenue drivers for the fourth quarter of 2020.

Number 1: HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion Healthcare, discussed how the company’s adalimumab biosimilar candidate, CT-P17, stands out from the competition.

To read all of these articles and more, visit centerforbiosimilars.com.